HER2-positive bosom diseases will in general be more forceful than different kinds of bosom malignant growth. Medicines that explicitly target HER2 are powerful. These medicines are successful to such an extent that the forecast for HER2-positive bosom disease is very acceptable. Certain standard chemotherapy tranquilizes likewise can be compelling in rewarding HER2-positive bosom tumors, in spite of the fact that these medications don't explicitly focus on the HER2 protein. Specialists suggest that each intrusive bosom malignancy be tried for the nearness of HER2 on the grounds that the outcomes fundamentally sway treatment proposals and choices. HER2 testing isn't done routinely for ductal carcinoma in situ, aside from as a ma jor aspect of a clinical preliminary.
Awards 2021: Journal of Oncology Medicine & Practice
Awards 2021: Journal of Oncology Medicine & Practice
Research Article: Journal of Oncology Medicine & Practice
Research Article: Journal of Oncology Medicine & Practice
Case Report: Journal of Oncology Medicine & Practice
Case Report: Journal of Oncology Medicine & Practice
Research Article: Journal of Oncology Medicine & Practice
Research Article: Journal of Oncology Medicine & Practice
Research Article: Journal of Oncology Medicine & Practice
Research Article: Journal of Oncology Medicine & Practice
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters & Accepted Abstracts: Cancer Science & Therapy
Posters & Accepted Abstracts: Pulmonary & Respiratory Medicine
Posters & Accepted Abstracts: Pulmonary & Respiratory Medicine
Accepted Abstracts: Journal of Forensic Research
Accepted Abstracts: Journal of Forensic Research
Accepted Abstracts: Alternative & Integrative Medicine
Accepted Abstracts: Alternative & Integrative Medicine
Scientific Tracks Abstracts: Cancer Science & Therapy
Scientific Tracks Abstracts: Cancer Science & Therapy
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report